Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Sarah H Cross , Arif H Kamal , Donald H Taylor Jr , et al Added: 3 years ago
Heart failure (HF) is estimated to affect 26 million people worldwide and is responsible for an annual global economic burden of US$108 billion.1,2 An ageing population and a reduction in mortality from other conditions such as acute MI are expected to result in an increased HF prevalence throughout much of the world.1,3–6 The prevalence of HF has particularly increased among those aged 85 years… View more
Job title: Cardiovascular Disease and Hospice & Palliative Medicine Fellow
Dr Sarah Godfrey, MD, MPH is acardiovascular disease and hospice and palliative medicine fellow at UT Southwestern Medical Center. She grew up in New Jersey, studied African and African American Studies at Harvard University, and then did the majority of her medical training at Columbia University (postbac program, medical school, MPH, and internal medicine residency). Her research focus is in… View more
Foreword

Article

Author(s): Andrew JS Coats , Giuseppe Rosano Added: 3 years ago
It is with great pleasure that we introduce to you, our readers, to volume 5, issue 2 of Cardiac Failure Review. This issue we are focusing on clinical syndromes and the impact and therapy of selected comorbidities commonly seen in the heart failure (HF) patient. Stolfo and Savarese take another look at the landmark trials of angiotensin-converting enzyme (ACE) inhibitors in HF from the… View more
Author(s): Lisa LeMond , Sarah J Goodlin Added: 3 years ago
In the infancy of the hospice and palliative care movements, Dame Cicely Saunders noted that terminally ill patients and their families were often told “there is nothing more to do.” Her unwavering belief was that those words betrayed the patient, and that “there is so much more to do.”1 Stage D heart failure (HF) is defined as HF in which refractory symptoms persist despite guideline-directed… View more
Author(s): Tonje Thorvaldsen , Lars H Lund Added: 3 years ago
Heart failure (HF) is associated with poor quality of life, high risk of death and is the leading cause of hospitalisation.1 With an ageing population and improved care for cardiovascular diseases, the prevalence of HF is increasing. Despite advances in HF therapies, 1–10% of the population with HF progress to an advanced stage of the disease.2,3 In the US, an estimated 250,000–300,000 patients… View more
Author(s): David Pham , Justin L Grodin Added: 3 years ago
Introduction Advances in heart failure medical therapy over the past few decades have improved the prognosis of patients with this condition. Despite this, heart failure remains a significant burden to the medical system as the incidence of heart failure hospitalisation continues to rise.1 Diuretics have been a mainstay of therapy in heart failure to relieve congestion and improve symptoms… View more
Author(s): Bao Tran , Gregg C Fonarow Added: 3 years ago
Heart failure (HF) remains a major public health problem resulting in substantial morbidity, mortality and healthcare expenditures globally. The European Society of Cardiology (ESC) 2012 Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure and the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) 2013 Guideline for the Management of Heart… View more
Author(s): Wan Xian Chan , Weiqin Lin , Raymond Ching Chiew Wong Added: 3 years ago
Southeast Asian nations are increasingly facing a higher burden of cardiovascular risk factors,1 which in turn correlate with a propensity towards cardiac-related diseases including heart failure (HF). In Singapore, HF is the most common cardiac cause of hospitalisation, accounting for 17 % of all cardiac admissions2 In 2015, public hospitals recorded in excess of 5,700 unique HF admissions.3 The… View more
Author(s): Edo Y Birati , Mariell Jessup Added: 3 years ago
Heart failure (HF) is a leading cause of morbidity and mortality worldwide, affecting 1–2% of the adult population in western countries with incidence of 5–10 per 1000 persons per year.1,2 It is estimated that the prevalence of HF will continue to increase as the population ages and, according to the American Heart Association (AHA), by the year 2030 the prevalence of HF in the US alone will rise… View more